Drug Profile
Etripamil - Milestone Pharmaceuticals
Alternative Names: (-)-MSP-2017; CARDAMYST; MSP-2017; MSP-2017A; MSP-2017BLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Milestone Pharmaceuticals
- Developer Ji Xing Pharmaceuticals; Milestone Pharmaceuticals
- Class Amines; Antiarrhythmics; Benzoates; Esters; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Paroxysmal supraventricular tachycardia
- Phase II Atrial fibrillation
- Phase I Unspecified
- No development reported Angina pectoris
Most Recent Events
- 16 Apr 2024 Milestone Pharmaceiticals has patents pending for Etripamil in USA, Canada, and Europe
- 08 Apr 2024 Efficacy data from a phase III NODE-303 in paroxysmal supraventricular tachycardia (PSVT) released by Milestone Pharmaceuticals
- 28 Mar 2024 Milestone Pharmaceuticals resubmits NDA to the US FDA for Paroxysmal supraventricular tachycardia